Anebulo Pharmaceuticals (FRA:214) ROCE % : -111.32% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Anebulo Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2024 was -111.32%.

Anebulo Pharmaceuticals ROCE % Historical Data

The historical data trend for Anebulo Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals ROCE % Chart

Anebulo Pharmaceuticals Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

ROCE %

-247.77

-40.36

-90.50

Anebulo Pharmaceuticals Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial										-78.19	-86.00	-108.43	-143.26	-111.32

Anebulo Pharmaceuticals ROCE % Calculation

Anebulo Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-10.877	/	( ( (14.738 - 0.485)	+	(10.771 - 0.987) )	/ 2 )
	=	-10.877	/	( (14.253	+	9.784)	/ 2 )
	=	-10.877	/	12.0185
	=	-90.50 %

Anebulo Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-5.864	/	( ( (6.878 - 0.93)	+	(5.516 - 0.929) )	/ 2 )
	=	-5.864	/	( ( 5.948	+	4.587 )	/ 2 )
	=	-5.864	/	5.2675
	=	-111.32 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Anebulo Pharmaceuticals (FRA:214) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Anebulo Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Anebulo Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (FRA:214) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ANEB:USA

Address

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734

Website

https://www.anebulo.com

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Anebulo Pharmaceuticals Headlines

No Headlines